SLC17A9 (solute carrier family 17 member 9) is a voltage-gated ATP nucleotide uniporter that transports ATP, ADP, and GTP across vesicular membranes using the membrane potential as the driving force 1. Primarily localized to lysosomes and secretory vesicles, SLC17A9 regulates ATP accumulation in lysosomes and controls ATP-dependent lysosomal proteins, while indirectly regulating ATP exocytosis in astrocytes, adrenal chr20 granules, and synaptic vesicles 123. SLC17A9 deficiency impairs lysosomal ATP content and compromises cell viability 3. Beyond normal physiology, SLC17A9 has emerged as a significant oncogenic modulator. Elevated SLC17A9 expression correlates with poor prognosis in multiple cancers: colorectal, gastric, and lung cancer, where it serves as an independent prognostic predictor 456. In clear cell renal cell carcinoma, SLC17A9 promotes cell growth and migration through KCNH1 regulation 7. In hepatocellular carcinoma, the HHEX-mediated ABI2/SLC17A9 axis maintains cancer stem cell properties 8. Additionally, SLC17A9 genetic polymorphisms are associated with phantom tooth pain susceptibility, suggesting roles in neuropathic pain pathways 9. Cardiac studies demonstrate SLC17A9-dependent ATP release from sympathetic neurons regulates NLRP3 inflammasome activation and pressure overload-induced cardiac hypertrophy 10.